Li Chun-Bo, Ning Yu-Ting, Shen Nai-Ying, Wang Ben, Xiao Han, Luo Gang
Department of General Surgery, No. 215 Hospital of Shaanxi Nuclear Industry, Xianyang 712000, Shaanxi Province, China.
Department of General Surgery, Xi'an Medical College, Xi'an 710000, Shaanxi Province, China.
World J Hepatol. 2025 Jul 27;17(7):107520. doi: 10.4254/wjh.v17.i7.107520.
Primary liver cancer, a common malignant tumor of the digestive tract, ranks fifth in global cancer incidence and shows high morbidity and mortality. Liver cancer patients who are diagnosed early have the option of surgical resection, which offers the possibility of a radical cure. However, due to the insidious disease onset, most patients are diagnosed in the intermediate or advanced stages, and surgery is no longer a viable option. Therefore, systemic treatment options play an essential role in the management of advanced liver cancer. These treatments aim to suppress disease progression, prolong survival, and improve quality of life. This article reviews the latest research in the field of systemic therapy of liver cancer, including molecular targeted therapy, immunotherapy, and their combination strategies. At first, the application and efficacy of first-line molecularly targeted drugs are discussed. Next, the revolutionary advances in immune checkpoint blockers are presented. Subsequently, the clinical effects of the combination of molecularly targeted therapy and immunotherapy are analyzed. Finally, this article summarizes the current challenges faced by the systemic treatment of liver cancer and introduces the prospect of future treatment trends.
原发性肝癌是一种常见的消化道恶性肿瘤，在全球癌症发病率中排名第五，具有高发病率和高死亡率。早期诊断出的肝癌患者可选择手术切除，这提供了根治的可能性。然而，由于疾病发病隐匿，大多数患者在中晚期才被诊断出来，手术已不再是可行的选择。因此，全身治疗方案在晚期肝癌的治疗中起着至关重要的作用。这些治疗旨在抑制疾病进展、延长生存期并提高生活质量。本文综述了肝癌全身治疗领域的最新研究，包括分子靶向治疗、免疫治疗及其联合策略。首先，讨论一线分子靶向药物的应用和疗效。其次，介绍免疫检查点阻断剂的革命性进展。随后，分析分子靶向治疗与免疫治疗联合的临床效果。最后，本文总结了肝癌全身治疗目前面临的挑战，并介绍了未来治疗趋势的前景。
